Mobile Developers Now Get Greater Control of Their Revenue, Ownership of Their Data, and Direct-to-Consumer Capabilities With New Features for Xsolla’s Leading Web Shop
Xsolla, a leading global video game commerce company, announces significant updates to its leading Web Shop solution for mobile games, a modular solution that enables mobile developers to quickly generate direct-to-consumer stores in minutes or build fully customized storefronts with advanced features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813375229/en/
(Graphic: Xsolla)
As developers face rising user acquisition costs and development expenses, varying regulations across regions, and high in-app fees, Xsolla Web Shop offers a strategic edge: a frictionless way to convert players into paying customers, retain them longer, expand monetization beyond the platforms, and operate LiveOps with more automation and reduced overhead.
Key benefits of the easy plug-in new features in Xsolla Web Shop include:
- Automated and simplified operations. Cut operational overhead by up to 50% using real-time catalog sync, dynamic bundles, and streamlined JSON import.
- Higher retention and lifetime value. Boost player retention by 15%+ and ARPPU by 20%+ with features designed to keep users coming back:
- Adaptive Offer Chains that evolve with each purchase to enhance satisfaction and increase spending.
- Subscriptions that deliver recurring benefits and long-term value.
- Discord Bot that brings commerce capabilities directly into Discord servers to mirror the Web Shop experience through messages and server channels.
- Social Quests that reward players for visiting a Discord server, viewing a YouTube video, and sharing events.
- Increased conversions: See over 30% conversion increase with upgraded browser-based PWA push notifications that re-engage players with event alerts, timed offers, and personal messages, right in their browser.
- Higher margins with Buy Button*. Earn up to 25% higher margins on U.S. iOS transactions by letting players pay directly from their game via a browser using a seamless, one-tap checkout.
- Optimized ROI with the widest coverage of MMPs (mobile measurement partners). Seamless integration to Appsflyer, Adjust (available now), and Singular (coming soon), enabling better attribution, campaign optimization, and performance tracking.
- Faster time-to-market. Decrease your time-to-market by 50% with a no-code, fully custom Web Shop built from custom blocks, widgets, and modules with the flexibility of Headless Storefront SDK.
For a complete list of new features and improvements, check out our Release Notes.
“With the new updates to Web Shop, we're giving developers a powerful extension of their in-game monetization,” said Chris Hewish, President at Xsolla. “It’s designed to perform, built for LiveOps, and aligned with the latest market dynamics. It's not just about long-term revenue, it's about operating smarter and maximizing the player relationship.”
With over 600 Web Shops launched globally, Xsolla’s partners have collectively demonstrated their effectiveness at scaling direct sales and creating lasting revenue streams outside traditional app store ecosystems. The new updates to Xsolla Web Shop provide studios with an even quicker and more seamless way to earn more substantial and long-term revenue, while retaining a larger share of every dollar that comes in.
With this release, Xsolla positions the Web Shop and the recently launched Buy Button for Mobile Games as a revenue stream and a foundational component of every mobile game’s LiveOps and D2C strategy.
To learn more or launch your Web Shop, visit www.xsolla.com/web-shop or talk to an expert.
For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25nextlevelwebshop
*April 30, 2025 U.S. District Court ruling
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813375229/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release
Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom